Caris Life Sciences, Inc. Financials
This page shows Caris Life Sciences, Inc. (CAI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Caris Life Sciences, Inc. has an operating margin of 5.6%, meaning the company retains $6 of operating profit per $100 of revenue. This results in a moderate score of 35/100, indicating healthy but not exceptional operating efficiency. This is up from -62.4% the prior year.
Caris Life Sciences, Inc.'s revenue surged 97.0% year-over-year to $812.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Caris Life Sciences, Inc. carries a low D/E ratio of 0.66, meaning only $0.66 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.85, Caris Life Sciences, Inc. holds $7.85 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Caris Life Sciences, Inc. has a free cash flow margin of 8.2%, earning a moderate score of 46/100. The company generates positive cash flow after capital investments, but with room for improvement.
Caris Life Sciences, Inc. generates a -11.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Caris Life Sciences, Inc. scores 4.58, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.5B) relative to total liabilities ($548.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Caris Life Sciences, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Caris Life Sciences, Inc. generates $-1.22 in operating cash flow ($83.2M OCF vs -$68.1M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Caris Life Sciences, Inc. earns $0.8 in operating income for every $1 of interest expense ($45.1M vs $56.8M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Caris Life Sciences, Inc. generated $812.0M in revenue in fiscal year 2025. This represents an increase of 97.0% from the prior year.
Caris Life Sciences, Inc.'s EBITDA was $67.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 132.5% from the prior year.
Caris Life Sciences, Inc. reported -$68.1M in net income in fiscal year 2025. This represents an increase of 75.8% from the prior year.
Caris Life Sciences, Inc. earned $-3.22 per diluted share (EPS) in fiscal year 2025. This represents an increase of 69.8% from the prior year.
Cash & Balance Sheet
Caris Life Sciences, Inc. generated $66.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 126.4% from the prior year.
Caris Life Sciences, Inc. held $796.3M in cash against $378.8M in long-term debt as of fiscal year 2025.
Caris Life Sciences, Inc. had 283M shares outstanding in fiscal year 2025. This represents an increase of 674.0% from the prior year.
Margins & Returns
Caris Life Sciences, Inc.'s operating margin was 5.6% in fiscal year 2025, reflecting core business profitability. This is up 67.9 percentage points from the prior year.
Caris Life Sciences, Inc.'s net profit margin was -8.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 60.0 percentage points from the prior year.
Caris Life Sciences, Inc.'s ROE was -11.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Caris Life Sciences, Inc. invested $101.6M in research and development in fiscal year 2025. This represents a decrease of 10.8% from the prior year.
Caris Life Sciences, Inc. spent $113K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Caris Life Sciences, Inc. invested $16.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 92.6% from the prior year.
CAI Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|
| Revenue | N/A | $216.8M+19.5% | $181.4M | N/A | $101.6M+1.6% | $100.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $21.6M-13.7% | $25.0M | N/A | $27.6M+11.5% | $24.8M |
| SG&A Expenses | N/A | $52.0M-19.3% | $64.4M | N/A | $40.9M-0.5% | $41.1M |
| Operating Income | N/A | $32.6M+281.5% | -$18.0M | N/A | -$60.8M+9.2% | -$67.0M |
| Interest Expense | N/A | $13.5M-29.7% | $19.2M | N/A | $13.8M+0.9% | $13.7M |
| Income Tax | N/A | $0 | $0 | N/A | $0 | $0 |
| Net Income | N/A | $24.3M+133.9% | -$71.8M | N/A | -$67.7M-2.3% | -$66.2M |
| EPS (Diluted) | N/A | $0.08+101.0% | $-7.97 | N/A | $-2.59-2.0% | $-2.54 |
CAI Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|
| Total Assets | $1.1B+14.3% | $984.6M+3.1% | $955.1M+177.8% | $343.7M | N/A | N/A |
| Current Assets | $997.8M+16.8% | $854.2M+2.5% | $833.3M+286.3% | $215.7M | N/A | N/A |
| Cash & Equivalents | $796.3M+5.7% | $753.2M+4.8% | $718.9M+1024.2% | $64.0M | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $112.1M+320.0% | $26.7M-47.5% | $50.9M-42.3% | $88.2M | N/A | N/A |
| Goodwill | $19.3M0.0% | $19.3M0.0% | $19.3M0.0% | $19.3M | N/A | N/A |
| Total Liabilities | $548.4M+8.3% | $506.2M+0.8% | $502.2M-82.3% | $2.8B | N/A | N/A |
| Current Liabilities | $127.1M+47.8% | $86.0M-4.6% | $90.2M-45.5% | $165.4M | N/A | N/A |
| Long-Term Debt | $378.8M+0.7% | $376.3M+0.7% | $373.6M+17.0% | $319.4M | N/A | N/A |
| Total Equity | $577.3M+20.7% | $478.4M+5.6% | $452.9M+118.1% | -$2.5B-2.3% | -$2.4B-3.5% | -$2.4B |
| Retained Earnings | -$2.5B+3.1% | -$2.6B+0.9% | -$2.7B-7.4% | -$2.5B | N/A | N/A |
CAI Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $44.8M-28.3% | $62.4M | N/A | -$38.9M+43.9% | -$69.4M | N/A |
| Capital Expenditures | $5.1M-28.3% | $7.1M | N/A | $2.3M+25.3% | $1.8M | N/A |
| Free Cash Flow | $39.7M-28.3% | $55.3M | N/A | -$41.2M+42.2% | -$71.3M | N/A |
| Investing Cash Flow | -$5.1M+28.3% | -$7.1M | N/A | -$2.3M-25.3% | -$1.8M | N/A |
| Financing Cash Flow | $3.4M+116.1% | -$21.1M | N/A | $226K+159.8% | $87K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $91K | $0 | N/A | $0 | $0 | N/A |
CAI Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | 15.0%+25.0pp | -9.9% | N/A | -59.9%+7.1pp | -67.0% |
| Net Margin | N/A | 11.2%+50.8pp | -39.6% | N/A | -66.6%-0.5pp | -66.1% |
| Return on Equity | N/A | 5.1%+20.9pp | -15.8% | N/A | N/A | N/A |
| Return on Assets | N/A | 2.5%+10.0pp | -7.5% | N/A | N/A | N/A |
| Current Ratio | 7.85-2.1 | 9.93+0.7 | 9.24+7.9 | 1.30 | N/A | N/A |
| Debt-to-Equity | 0.66-0.1 | 0.79-0.0 | 0.82+1.0 | -0.13 | N/A | N/A |
| FCF Margin | N/A | 25.5% | N/A | N/A | -70.1% | N/A |
Similar Companies
Frequently Asked Questions
What is Caris Life Sciences, Inc.'s annual revenue?
Caris Life Sciences, Inc. (CAI) reported $812.0M in total revenue for fiscal year 2025. This represents a 97.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Caris Life Sciences, Inc.'s revenue growing?
Caris Life Sciences, Inc. (CAI) revenue grew by 97% year-over-year, from $412.3M to $812.0M in fiscal year 2025.
Is Caris Life Sciences, Inc. profitable?
No, Caris Life Sciences, Inc. (CAI) reported a net income of -$68.1M in fiscal year 2025, with a net profit margin of -8.4%.
What is Caris Life Sciences, Inc.'s EBITDA?
Caris Life Sciences, Inc. (CAI) had EBITDA of $67.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Caris Life Sciences, Inc. have?
As of fiscal year 2025, Caris Life Sciences, Inc. (CAI) had $796.3M in cash and equivalents against $378.8M in long-term debt.
What is Caris Life Sciences, Inc.'s operating margin?
Caris Life Sciences, Inc. (CAI) had an operating margin of 5.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Caris Life Sciences, Inc.'s net profit margin?
Caris Life Sciences, Inc. (CAI) had a net profit margin of -8.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Caris Life Sciences, Inc.'s return on equity (ROE)?
Caris Life Sciences, Inc. (CAI) has a return on equity of -11.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Caris Life Sciences, Inc.'s free cash flow?
Caris Life Sciences, Inc. (CAI) generated $66.9M in free cash flow during fiscal year 2025. This represents a 126.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Caris Life Sciences, Inc.'s operating cash flow?
Caris Life Sciences, Inc. (CAI) generated $83.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Caris Life Sciences, Inc.'s total assets?
Caris Life Sciences, Inc. (CAI) had $1.1B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Caris Life Sciences, Inc.'s capital expenditures?
Caris Life Sciences, Inc. (CAI) invested $16.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Caris Life Sciences, Inc. spend on research and development?
Caris Life Sciences, Inc. (CAI) invested $101.6M in research and development during fiscal year 2025.
What is Caris Life Sciences, Inc.'s current ratio?
Caris Life Sciences, Inc. (CAI) had a current ratio of 7.85 as of fiscal year 2025, which is generally considered healthy.
What is Caris Life Sciences, Inc.'s debt-to-equity ratio?
Caris Life Sciences, Inc. (CAI) had a debt-to-equity ratio of 0.66 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Caris Life Sciences, Inc.'s return on assets (ROA)?
Caris Life Sciences, Inc. (CAI) had a return on assets of -6.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Caris Life Sciences, Inc.'s Altman Z-Score?
Caris Life Sciences, Inc. (CAI) has an Altman Z-Score of 4.58, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Caris Life Sciences, Inc.'s Piotroski F-Score?
Caris Life Sciences, Inc. (CAI) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Caris Life Sciences, Inc.'s earnings high quality?
Caris Life Sciences, Inc. (CAI) has an earnings quality ratio of -1.22x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Caris Life Sciences, Inc. cover its interest payments?
Caris Life Sciences, Inc. (CAI) has an interest coverage ratio of 0.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Caris Life Sciences, Inc.?
Caris Life Sciences, Inc. (CAI) scores 61 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.